206434-77-7

Basic information

• Product Name: Methanone, (4-fluorophenyl)[6-methoxy-2-(4-methoxyphenyl)benzo[b]thien-3-yl]-
• CAS NO: 206434-77-7
• Molecular Formula: C23H17FO3S
• Molecular Weight: 392.451
• Mol File: 206434-77-7.mol
• Article Data: 9

Chemical Properties

• CAS DataBase Reference: Methanone, (4-fluorophenyl)[6-methoxy-2-(4-methoxyphenyl)benzo[b]thien-3-yl]-(CAS DataBase Reference)
• NIST Chemistry Reference: Methanone, (4-fluorophenyl)[6-methoxy-2-(4-methoxyphenyl)benzo[b]thien-3-yl]-(206434-77-7)
• EPA Substance Registry System: Methanone, (4-fluorophenyl)[6-methoxy-2-(4-methoxyphenyl)benzo[b]thien-3-yl]-(206434-77-7)

Safety Data

• Hazardous Substances Data: 206434-77-7(Hazardous Substances Data)

Upstream product

• 132993-23-8 4-fluorophenyl trifluoromethanesulfonate 
• 2632-13-5 2-Bromo-4'-methoxyacetophenone 
• 15570-12-4 3-methoxybenzenethiol 
• 63675-73-0 α-(3-methoxyphenyl-thio)-4-methoxyacetophenone 
• 111359-29-6 6-methoxy-N,N-dimethylbenzo[b]thiophen-2-amine 
• 403-43-0 4-fluorobenzoyl chloride 
• 13139-86-1 4-methoxyphenyl magnesium bromide 
• 243845-88-7 (2-dimethylamino-6-methoxy-benzo[b]thiophen-3-yl)-(4-fluoro-phenyl)-methanone 
• 63675-74-1 2-(4'-methoxyphenyl)-6-methoxybenzothiophene 

Downstream Products

• 220655-23-2 (4-(2-hydroxyethoxy)phenyl)(6-methoxy-2-(4-methoxyphenyl)benzo[b]thiophen-3-yl)methanone 

Relevant articles and documents

Benzothiophene derivatives as selective estrogen receptor covalent antagonists: Design, synthesis and anti-ERα activities

Estrogen receptor α emerged as a well validated therapeutic target of breast cancer for decades. However, approximately 50% of patients who initially responding to standard-of-care (SoC), such as undergo therapy of Tamoxifen, generally inevitably progress to an endocrine-resistance ER+ phenotype. Recently, selective estrogen receptor covalent antagonists (SERCAs) targeted to ERα have been demonstrated as a therapeutic alternative. In the present study, series of novel 6-OH-benzothiophene (BT) derivatives targeting ERα and deriving from Raloxifene were designed, synthesized, and biologically evaluated as covalent antagonists. Driven by the antiproliferative efficacy in ER+ breast cancer cells, our chemical optimization finally led to compound 19d that with potent antagonistic activity in ER+ tumor cells while without agonistic activity in endometrial cells. Moreover, the docking simulation was carried out to elucidate the binding mode, revealing 19d as an antagonist and covalently binding to the cysteine residue at the 530 position of ER helix H11.

A Nickel-Catalyzed Carbonyl-Heck Reaction

The use of transition-metal catalysis to enable the coupling of readily available organic molecules has greatly enhanced the ability of chemists to access complex chemical structures. In this work, an intermolecular coupling reaction that unites organotriflates and aldehydes is presented. A unique catalyst system is identified to enable this reaction, featuring a Ni0 precatalyst, a tridentate Triphos ligand, and a bulky amine base. This transformation provides access to a variety of ketone-containing products without the selectivity- and reactivity-related challenges associated with more traditional Friedel–Crafts reactions. A Heck-type mechanism is postulated, wherein the π bond of the aldehyde takes the role of the olefin in the insertion/elimination steps.

Discovery of a New Class of Liver Receptor Homolog-1 (LRH-1) Antagonists: Virtual Screening, Synthesis and Biological Evaluation

-